Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 85-95

  Nagaraj, Chandran ^a   Tang, Bi ^a   Bálint, Zoltán ^a   Wygrecka, Malgorzata ^b   Hrzenjak, Andelko ^a   Kwapiszewska, Grazyna ^a   Stacher, Elvira ^a   Lindenmann, Joerg ^a   Weir, E Kenneth ^c   Olschewski, Horst ^a   Olschewski, Andrea ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Pulmonary artery pressure; Resting membrane potential; Src tyrosine kinase; TWIK related acid sensitive potassium 1 channel

Indexed keywords

CALCIUM ION; POTASSIUM CHANNEL; PROTEIN TYROSINE KINASE; SRC TYROSINE KINASE; TWIK RELATED ACID SENSITIVE POTASSIUM 1 CHANNEL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOLOCALIZATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PULMONARY ARTERY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

CELLS, CULTURED; HUMANS; MYOCYTES, SMOOTH MUSCLE; POTASSIUM CHANNELS; PULMONARY ARTERY; SRC-FAMILY KINASES;

EID: 84872202945     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00211811     Document Type: Article

References (35)

1. Weir EK, Olschewski A. Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc Res 2006; 71: 630-641.
2. Gurney AM, Osipenko ON, MacMillan D, et al. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003; 93: 957-964.
3. Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006; 98: 1072-1080.
4. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2: 467-475.
5. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-480.
6. Dai S, Hall DD, Hell JW. Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol Rev 2009; 89: 411-452.
7. Holmes TC, Fadool DA, Ren R, et al. Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain. Science 1996; 274: 2089-2091.
8. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
9. Kreneisz O, Benoit JP, Bayliss DA, et al. AMP-activated protein kinase inhibits TREK channels. J Physiol 2009; 587: 5819-5830.
10. Tang B, Li Y, Nagaraj C, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009; 41: 476-483.
11. Czirjak G, Petheo GL, Spat A, et al. Inhibition of TASK-1 potassium channel by phospholipase C. Am J Physiol Cell Physiol 2001; 281: C700-C708.
12. Gurney AM, Osipenko ON, MacMillan D, et al. Potassium channels underlying the resting potential of pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 2002; 29: 330-333.
13. + channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351: 726-727.
14. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104: 11418-11423.
15. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406.
16. Mandegar M, Fung YC, Huang W, et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004; 68: 75-103.
17. Post JM, Hume JR, Archer SL, et al. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262: C882-C890.
18. 2+ in pulmonary and cerebral arterial myocytes. Am J Physiol 1993; 265: L591-L597.
19. 2+ in cultured human pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 2005; 288: C245-C252.
20. 2+ influx. EMBO J 2003; 22: 4337-4345.
21. 2+ sensitization during sustained hypoxic pulmonary vasoconstriction is endothelium dependent. Am J Physiol Lung CellMol Physiol 2003; 284: L1121-L1126.
22. Weir EK, Cabrera JA, Mahapatra S, et al. The role of ion channels in hypoxic pulmonary vasoconstriction. Adv Exp Med Biol 2010; 661: 3-14.
23. Holmes TC, Berman K, Swartz JE, et al. Expression of voltage-gated potassium channels decreases cellular protein tyrosine phosphorylation. J Neurosci 1997; 17: 8964-8974.
24. Kirkegaard SS, Lambert IH, Gammeltoft S, et al. Activation of the TASK-2 channel after cell swelling is dependent on tyrosine phosphorylation. Am J Physiol Cell Physiol 2010; 299: C844-C853.
25. + channels as a new mechanism of agonist-induced vasoconstriction. Proc Natl Acad Sci USA 2002; 99: 14560-14565.
26. Knock GA, Snetkov VA, Shaifta Y, et al. Role of src-family kinases in hypoxic vasoconstriction of rat pulmonary artery. Cardiovasc Res 2008; 80: 453-462.
27. 2+-sensitization of rat pulmonary artery. Cardiovasc Res 2008; 77: 570-579.
28. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-374.
29. Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208: 535-548.
30. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
31. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
32. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 37: 1104-1118.
33. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
34. Dumitrescu D, Seck C, ten Freyhans H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218-220.
35. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-968.